JPS646293A - N-(nalpha-(1(s)-carboxy-3-cyclohexylpropyl)-l-lysyl)-n-cyclopent ylglycine - Google Patents
N-(nalpha-(1(s)-carboxy-3-cyclohexylpropyl)-l-lysyl)-n-cyclopent ylglycineInfo
- Publication number
- JPS646293A JPS646293A JP63070631A JP7063188A JPS646293A JP S646293 A JPS646293 A JP S646293A JP 63070631 A JP63070631 A JP 63070631A JP 7063188 A JP7063188 A JP 7063188A JP S646293 A JPS646293 A JP S646293A
- Authority
- JP
- Japan
- Prior art keywords
- cyclohexylpropyl
- lysyl
- carboxy
- ylglycine
- nalpha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
NEW MATERIAL:N-[N<alpha>-( 1-(S)-carboxy-3-cyclohexylpropyl )-L-lysyl]-N-cyclopentyl glycine and its salt. USE:A transferase-inhibitor and a hypotensor. PREPARATION:A ketone of formula I (R1 is OH, lower alkoxy, lower aralkoxy or cycloalkoxy) is made to react with a protected peptide of formula II (R2 is OH, lower alkoxy, lower aralkoxy or cycloalkoxy; R3 is protecting group other than H) in the presence of a reducing agent and, as necessary, the protect ing group is removed from the product and the compound is optionally converted to a salt. The product is purified by chromatography or fractional recrystallization and, as necessary, the protecting group is removed to properly separate an isomer having higher biological activity.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63070631A JPS646293A (en) | 1987-03-24 | 1988-03-24 | N-(nalpha-(1(s)-carboxy-3-cyclohexylpropyl)-l-lysyl)-n-cyclopent ylglycine |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP6777087 | 1987-03-24 | ||
| JP63070631A JPS646293A (en) | 1987-03-24 | 1988-03-24 | N-(nalpha-(1(s)-carboxy-3-cyclohexylpropyl)-l-lysyl)-n-cyclopent ylglycine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS646293A true JPS646293A (en) | 1989-01-10 |
Family
ID=26408983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP63070631A Pending JPS646293A (en) | 1987-03-24 | 1988-03-24 | N-(nalpha-(1(s)-carboxy-3-cyclohexylpropyl)-l-lysyl)-n-cyclopent ylglycine |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS646293A (en) |
-
1988
- 1988-03-24 JP JP63070631A patent/JPS646293A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK126389D0 (en) | PEPTIDE COMPOUNDS | |
| FI940105A0 (en) | Processes for the preparation of sertraline intermediates | |
| ES8500230A1 (en) | Derivatives from tricyclic amino acids, process for their preparation, compounds containing them and their use, as well as bicyclic amino acids as intermediates and process for their preparation. | |
| AU6954887A (en) | Oligopeptidyl nitrile derivatives, agents containing them, a process for their preparation, and their use | |
| ES477832A1 (en) | Amino-dibenzopyrans, their preparation, formulations containing them and their use as pharmaceuticals. | |
| KR910700062A (en) | Deletion homologues of marganine peptides | |
| HUT71798A (en) | Process for preparing pharmaceutical compositions of antidepressant activity containing 2-amino-6-a-propylamino-4,5,6,7-tetrahydrobenzothiazole (pramipexol) | |
| JPS5630978A (en) | Novel mitomycin and its preparation | |
| DE69204840D1 (en) | Process for the preparation of sertraline. | |
| DK149091C (en) | METHOD OF ANALOGUE FOR THE PREPARATION OF PEPTIDS CONTAINING 2-7 AMINO ACID RESIDUES, DESAMINODIPEPTIDES OR AMIDES THEREOF WITH UBIQUITIN SIMILAR ACTIVITY OR PHARMACEUTICAL ACCEPTABLE ACID ADDITIONAL SALTS | |
| JPS646293A (en) | N-(nalpha-(1(s)-carboxy-3-cyclohexylpropyl)-l-lysyl)-n-cyclopent ylglycine | |
| ES2104688T3 (en) | A PROCEDURE FOR THE PREPARATION OF A TIO-3-CEFEM 3-SUBSTITUTED COMPOUND. | |
| DE69416003D1 (en) | Kristalline, polymorphische form von (s,s,s)-n-(1-[2-carboxy-3-(n2-mesyllysylamino)propyl]-1-cyclopentylcarbonyl)tyrosin | |
| JPS55164672A (en) | Azetidine derivative and its preparation | |
| DK0410278T3 (en) | Pure inhibiting amino oligohydroxy derivatives | |
| DE69423042D1 (en) | PROTECTIVE GROUP FOR USE IN OLIGODEOXYRIBONUCLEOTID SYNTHESIS | |
| ATE94168T1 (en) | PEPTIDES. | |
| IT1216865B (en) | ARGININIC DERIVATIVE, PROCEDURE FOR ITS PREPARATION AND ITS USE IN PEPTIDAL SYNTHESIS. | |
| BR9107286A (en) | Protective compound group of protected compound protected device process for the synthesis or separation of a mixture of compounds and use of a group | |
| ES2096559T3 (en) | INTERFERON GAMMA HUMANO, PROCEDURE FOR THE PREPARATION OF SUCH INTERFERON GAMMA HUMANO, AND ITS USE. | |
| JPS55164671A (en) | Azetidine derivative and its preparation | |
| JPS5620572A (en) | 4-tert-butylbenzamide derivative and antimicrobial containing the same | |
| IT8421256A1 (en) | PROCEDURE FOR PURIFICATION OF URANIFERE AND / OR MOLYBDENIFERE ORGANIC SOLUTIONS CONTAINING ZIRCONIUM AND / OR AFNIUM AMONG OTHER IMPURITIES | |
| JPS6485966A (en) | Benzoylurea-based compound, harmful animal controller containing said compound and production thereof | |
| ES8305307A1 (en) | Peptide, process for preparation thereof and use thereof. |